Aytu BioPharma is a commercial-stage company that sells ADHD and pediatric medicines and, since its launch in early 2026, EXXUA for major depressive disorder, which it markets in the U.S. under license.
Aytu's case rests on EXXUA (gepirone), an antidepressant whose label carries no warning about sexual dysfunction, which it launched in the U.S. in January 2026. EXXUA brought in $3.9 million in the June quarter, its first full quarter, while older ADHD medicines facing generics fell to $45.8 million for fiscal 2026. With $26.3 million in cash and no stated runway, the case depends on EXXUA growing fast enough to replace falling ADHD sales without new financing.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: EXXUA sales keep growing quickly
Does EXXUA keep growing fast enough to offset falling ADHD sales?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Aytu's EXXUA antidepressant brought in $3.9 million in its first full quarter of launch as ADHD sales fell to $10.4 million; the company was near break-even in the June quarter with $26.3 million in cash
EXXUA's commercial ramp in a crowded MDD market tests whether a differentiated 5-HT1A mechanism can achieve self-sustaining revenue before cash depletes
Aytu licenses U.S. rights to EXXUA (gepirone), an FDA-approved antidepressant
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Psychiatric disorders, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
8 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.